Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of metformin and pioglitazone in treatment of non-alcoholic fatty liver disease
IRCT20150706023083N2Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of metformin and pioglitazone in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Tabriz University of Medical Sciences. Started May 2019; status: completed.
02
Drugs
metforminpioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20150706023083N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150706023083N2.